中国药房2017，Vol.28Issue(23)：3212-3216,5.DOI:10.6039/j.issn.1001-0408.2017.23.12
多西他赛、表柔比星联合环磷酰胺对不同分子分型乳腺癌患者临床疗效及肿瘤标志物表达的影响
Effects of Docetaxel and Epirubicin Combined with Cyclophosphamide on Clinical Efficacy and Tumor Markers of Breast Cancer Patients with Different Molecular Types
王松 1薛文华 1赵晓玉 1梁艳 1齐跃东 1康健 1高明2
作者信息
- 1. 郑州大学第一附属医院药学部,郑州 450052
- 2. 郑州大学第一附属医院肿瘤科,郑州 450052
- 折叠
摘要
Abstract
OBJECTIVE:To investigate the effects of neoadjunctive chemotherapy(NAC)of docetaxel and epirubicin com-bined with cyclophosphamide on clinical efficacy and tumor markers of breast cancer patients with different molecular types. METH-ODS:A total of 88 female patients with locally advanced breast cancer collected from our hospital during Jan. 2014-Jan. 2016 were divided into Luminal A type(23 cases),Luminal B type(21 cases),basal-like type(11 cases),HER2-over expressing type(18 cases)and normal breast-like type(15 cases)according to molecular type. All patients were given Docetaxel injection+Epirubicin hydrochloride injection+Cyclophosphamide for injection for consecutive 6 cycles(21 d as a cycle). Total response rates and patho-logical complete remission(pCR)rates were compared among breast cancer patients with different molecular types. The expression of serum tumor markers [CEA,CA125,CA153] were compared before and after treatment,and the occurrence of ADR was record-ed. RESULTS:Total response rate of 88 patients was 63.64%,among which that of basal-like breast cancer patients was 72.73%, significantly higher than other molecular types,with statistical significance(P<0.05). There was no statistical significance in total response rates of pairwise molecular type comparison(P>0.05). The pCR rate of 88 patients was 27.27%,and that of basal-like breast cancer patients was the highest(45.45%). There was statistical significance in pCR rates of pairwise molecular type compari-son(P<0.05),except there was no significant difference in pCR rate between HER2-over expressing type and normal breast-like type(P>0.05). Before treatment,there was no statistical significance in the expression of CEA,CA125 and CA153 in breast can-cer patients with different molecular types(P>0.05). After treatment,the expression of CEA,CA125 and CA153 in different mo-lecular types were decreased significantly,with statistical significance(P<0.05). There was no statistical significance in the expres-sion of above markers among different molecular types(P>0.05). There was no statistical significance in the incidence of ADR among different molecular types(P>0.05). CONCLUSIONS:NAC plan of docetaxel and epirubicin combined with cyclophospha-mide can reduce the expression of tumor markers and shows certain therapeutic efficacy for breast cancer patients with different mo-lecular types. Total response rate and pCR rate of basal-like type are better than those of other molecular types,so NAC plan is the preferred treatment for basal-like type breast cancer.关键词
多西他赛/表柔比星/环磷酰胺/新辅助化疗/乳腺癌/分子分型/病理完全缓解/肿瘤标志物Key words
Docetaxel/Epirubicin/Cyclophosphamide/Neoadjunctive chemotherapy/Breast cancer/Molecular type/Patho-logical complete remission/Tumor markers分类
医药卫生引用本文复制引用
王松,薛文华,赵晓玉,梁艳,齐跃东,康健,高明..多西他赛、表柔比星联合环磷酰胺对不同分子分型乳腺癌患者临床疗效及肿瘤标志物表达的影响[J].中国药房,2017,28(23):3212-3216,5.
